KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2016 - 2025)

Regeneron Pharmaceuticals has reported Non-Current Deffered Revenue over the past 17 years, most recently at $208.7 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $208.7 million for Q4 2025, up 12.39% from a year ago — trailing twelve months through Dec 2025 was $208.7 million (up 12.39% YoY), and the annual figure for FY2025 was $208.7 million, up 12.39%.
  • Non-Current Deffered Revenue for Q4 2025 was $208.7 million at Regeneron Pharmaceuticals, down from $219.2 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for REGN hit a ceiling of $219.2 million in Q3 2025 and a floor of $27.0 million in Q1 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $120.8 million (2023), compared with a mean of $125.7 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: fell 4.77% in 2022 and later soared 155.22% in 2023.
  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue stood at $73.3 million in 2021, then dropped by 4.77% to $69.8 million in 2022, then surged by 81.52% to $126.7 million in 2023, then skyrocketed by 46.57% to $185.7 million in 2024, then rose by 12.39% to $208.7 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $208.7 million (Q4 2025), $219.2 million (Q3 2025), and $206.3 million (Q2 2025) per Business Quant data.